This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Biomarker News

February 2017: PATH received the Excellence in Partnering award from the CDC National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.  This was a competitive award and PATH was selected from three nominations.

 

PRESS RELEASE

Landmark Study Defines Normal Ranges for Testosterone Levels

January 10, 2017

New defined reference range can help limit misdiagnoses and unnecessary treatments

Washington, DC - A large study of more than 9,000 men has established harmonized reference ranges for total testosterone in men that when applied to assays that have been appropriately calibrated will effectively enable clinicians to make a correct diagnosis of hypogonadism, according to a new study published in the Endocrine Society’s The Journal of Clinical Endocrinology & Metabolism.

Testosterone is the main sex hormone in men, though women have testosterone as well in smaller amounts. Hypogonadism, a condition characterized by low testosterone levels, can lead to sexual    dysfunction, decreased muscle and bone strength, less energy, and lower fertility. The correct diagnosis and effective treatment and prevention of hypogonadism as well as many other diseases depend on accurate measurement of hormones, but lack of both defined reference ranges of testosterone and standardization of hormone assays has made diagnosing hypogonadism a difficult task.  “Well-defined reference ranges are at the heart of clinical practice and without them clinicians can make erroneous diagnoses that could lead to patients receiving costly, lifelong treatments that they don’t need or deny treatments to those who need them,” said Shalender Bhasin, MD, of Brigham and Women’s Hospital, Harvard Medical School in Boston, MA and lead author of the study. “Our data establish a reference range for testosterone. These data also show that variations in assays is an important contributor to variation in testosterone levels in cohorts from different geographic regions.  Clearly we need standardization in all hormone assays.”

In this study, researchers obtained serum testosterone samples from men who had already had their testosterone levels assayed locally. The samples were sent to the Centers for Disease Control and Prevention’s (CDC) Clinical Standardization Programs at the National Center for Environmental Health where testosterone concentrations were measured using a higher order liquid chromatography tandem mass spectrometry method. Researchers used the results from both measurements to generate harmonized values, which were in turn used to derive standardized, age-specific reference ranges overall. The harmonized normal range for testosterone in a non-obese population of European and American Men, 19-39 years, is 264-916 ng/dL.

“Without harmonized reference ranges and standardized assays, tests can lead to misdiagnoses and unfortunately this happens every day around the world,” said Hubert Vesper, PhD who is also a coauthor of the study and co-chair of The Partnership for the Accurate Testing of Hormones (PATH). “Now we have a reference range for testosterone, and it’s important that we take this into consideration in the tests that clinicians and patients depend on for accurate diagnoses.”

PATH provides technical and scientific support to the CDC Steroid Hormone Standardization Program, conducts educational activities on hormone measurement, and advocates for the universal use of standardized hormone tests, where available.

The study, “Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the USA and Europe,” will be published online ahead of print. Other authors of the study include: Thomas Travison of Harvard Medical School in Boston, MA; Eric Orwoll and Ying Wang of Oregon Health and Science University in Portland, OR; Frederick Wu of The

University of Manchester in Manchester, UK; Jean Marc Kaufman, Bruno Lapauw and Tom Fiers of Ghent University Hospital in Ghent, Belgium; and Alvin Matsumoto of the University of Washington School of Medicine in Seattle, WA.

National Association of Chronic Disease Directors
325 Swanton Way
Decatur, GA 30030
info@chronicdisease.org
(770) 458-7400
Hours of Operation: Mon. - Fri., 8 a.m. - 4:30 p.m.